Not available
Quote | Nightstar Therapeutics plc (NASDAQ:NITE)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $25.41 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 06/11/2019 09:43:06 am |
News | Nightstar Therapeutics plc (NASDAQ:NITE)
Note: This article was first made available to members of my exclusive community, The Formula , on May 14 when shares of Adverum ( ADVM ) were trading just over $6. Read: Adverum's most quarterly filing Read: ADVM-022 article (preclinical findings) Gene therapy - op...
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc...
Message Board Posts | Nightstar Therapeutics plc (NASDAQ:NITE)
Subject | By | Source | When |
---|---|---|---|
Cryptanite Receives MSB Status in the US - | 1 day sun 4 all | investorshub | 12/14/2018 2:51:09 PM |
Oct 24, 2018 - Subsidiary in Malta | 1 day sun 4 all | investorshub | 10/26/2018 3:14:02 PM |
CRYPTANITE wins award for internet/blockchain innovation! | 1 day sun 4 all | investorshub | 10/26/2018 3:11:32 PM |
The stock should move by the end of | anna1703 | investorshub | 10/25/2018 10:15:58 AM |
Finished the week with a 350,000 share day | GOLD DIGGAA | investorshub | 06/30/2018 1:09:08 PM |
News, Short Squeeze, Breakout and More Instantly...
Nightstar Therapeutics plc Company Name:
NITE Stock Symbol:
NASDAQ Market:
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 07, 2019 (GLOBE NEWSWIRE...
CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited ret...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY RESTRICTED JURISDICTION OR ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION WALTHAM, Mass. and LONDON, June 05, 2019 (GLOBE NEWSWIRE...